The data reported this morning by Amarin are “stunning” and upend “years of skepticism about the long-term heart benefit of products containing omega-3 fatty acids,” STAT’s Adam Feuerstein reports. Amarin’s Vascepa significantly reduced the risk of deaths, heart attacks, strokes and other serious cardiovascular events compared to a placebo, Feuerstein says. He points out that Amarin designed its cardiovascular outcomes study, known as REDUCE-IT, hoping to show Vascepa could meet the primary endpoint with a 15% risk reduction. The company this morning reported a 25% reduction. Vascepa could be the next cardiovascular blockbuster therapy, potentially prescribed to millions of Americans, Feuerstein predicts. Shares of Amarin in premarket trading are up 176%, or $5.25, to $8.24.